Long-Acting Antibody Candidate Neutralizes COVID-19 Variants
AstraZeneca recently highlighted new data at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), reinforcing its ambition to provide long-lasting immunity for millions globally.
For example, data featuring AZD3152, AstraZeneca’s investigational long-acting COVID-19 antibody, shows the investigational COVID-19 long-acting antibody neutralizes all known variants of concern identified to date.
Iskra Reic, Executive Vice President, Vaccines and Immune Therapies, AstraZeneca, stated in a press release on April 14, 2023, “Our first in vitro data from our next generation long-acting antibody, AZD3152, shows its potential to protect the immunocompromised from all known COVID-19 variants of concern to date.”
Last updated on April 3, 2023, the aim of the phase I/III clinical study is to evaluate the safety and neutralizing activity of AZD3152 compared with AZD7442 for pre-exposure prophylaxis of COVID-19 and separately evaluate the safety and PK of AZD5156, a combination of AZD3152 and AZD1061.
Other COVID-19 antibody news is posted by CoronavirusToday.com.